July 2025
1. AGARWAL R, Bertaina A, Soco C, Long-Boyle JR, et al
   Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial.
   Nat Med. 2025 Jul 22. doi: 10.1038/s41591-025-03817.
   

   >> Share

   
   
2. 
   Mapping circulating hematopoietic stem cells for non-invasive, blood-based diagnostics.
   Nat Med. 2025 Jul 10. doi: 10.1038/s41591-025-03803.
   

   >> Share

   
   
3. GRIMLEY M, Davies SM, Shrestha A, Shova A, et al
   Lentiviral gene therapy with reduced-intensity conditioning for sickle cell disease: a phase 1/2 trial.
   Nat Med. 2025;31:2204-2212.
   

   >> Share

   
   June 2025
4. CHEN JT, Dadheech N, Tan EHP, Ng NHJ, et al
   Stem cell therapies for diabetes.
   Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03767.
   

   >> Share

   
   
5. FURER N, Rappoport N, Milman O, Tavor S, et al
   A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.
   Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03716.
   

   >> Share

   
   
6. HEALEY N
   Stem cell therapies advance in Parkinson's disease and beyond.
   Nat Med. 2025 Jun 4. doi: 10.1038/d41591-025-00036.
   

   >> Share

   
   
7. MOLTENI R, Fiumara M, Campochiaro C, Alfieri R, et al
   Mechanisms of hematopoietic clonal dominance in VEXAS syndrome.
   Nat Med. 2025;31:1911-1924.
   

   >> Share

   
   April 2025
8. O'LEARY K
   Progress with stem cell therapy in Parkinson's disease.
   Nat Med. 2025 Apr 30. doi: 10.1038/d41591-025-00029.
   

   >> Share

   
   March 2025
9. RASH BG, Ramdas KN, Agafonova N, Naioti E, et al
   Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial.
   Nat Med. 2025 Mar 10. doi: 10.1038/s41591-025-03559.
   

   >> Share

   
   February 2025
10. MULLER A, Sullivan J, Schwarzer W, Wang M, et al
    High-efficiency base editing in the retina in primates and human tissues.
    Nat Med. 2025;31:490-501.
    

    >> Share

    
    December 2024
11. O'LEARY K
    Stem cells reverse type 1 diabetes.
    Nat Med. 2024;30:3393.
    

    >> Share

    
    November 2024
12. 
    HIV-1 remission following stem cell transplant without CCR5Delta32 mutation.
    Nat Med. 2024 Nov 6. doi: 10.1038/s41591-024-03365.
    

    >> Share

    
    October 2024
13. SVENDSEN SP, Svendsen CN
    Cell therapy for neurological disorders.
    Nat Med. 2024;30:2756-2770.
    

    >> Share

    
    
14. DIEZ-DIEZ M, Ramos-Neble BL, de la Barrera J, Silla-Castro JC, et al
    Unidirectional association of clonal hematopoiesis with atherosclerosis development.
    Nat Med. 2024;30:2857-2866.
    

    >> Share

    
    September 2024
15. SAEZ-CIRION A, Mamez AC, Avettand-Fenoel V, Nabergoj M, et al
    Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells.
    Nat Med. 2024 Sep 2. doi: 10.1038/s41591-024-03277.
    

    >> Share

    
    
16. CHEN X, Huang Y, Huang L, Huang Z, et al
    A brain cell atlas integrating single-cell transcriptomes across human brain regions.
    Nat Med. 2024;30:2679-2691.
    

    >> Share

    
    June 2024
17. CHEN YB, Mohty M, Zeiser R, Teshima T, et al
    Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
    Nat Med. 2024 Jun 6. doi: 10.1038/s41591-024-03016.
    

    >> Share

    
    May 2024
18. ZINTER MS, Dvorak CC, Mayday MY, Reyes G, et al
    Pathobiological signatures of dysbiotic lung injury in pediatric patients undergoing stem cell transplantation.
    Nat Med. 2024 May 23. doi: 10.1038/s41591-024-02999.
    

    >> Share

    
    
19. KELLY K, Bloor AJC, Griffin JE, Radia R, et al
    Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease.
    Nat Med. 2024 May 22. doi: 10.1038/s41591-024-02990.
    

    >> Share

    
    
20. HOUOT R, Bachy E, Cartron G, Gros FX, et al
    Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.
    Nat Med. 2024 May 14. doi: 10.1038/s41591-024-03053.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share